Promotional material intended for UK Healthcare Professionals only.
Prescribing information and adverse event reporting details can be found overpage.

Scotland

Ordering Glucarpidase▼ (Voraxaze) via Oxford Pharmacy Store (OPS)

IN WORKING HOURS (Only between 9am-5pm Mon-Fri, excluding England Bank Holidays)	OUT OF HOURS (Only between 5pm-10pm Mon-Fri, 9am-5pm Sat/Sun/Bank Holidays)
Please request your Pharmacy Procurement team send a Purchase Order to: Email: ops.orders@oxfordhealth.nhs.uk Tel: 01865 904141 EDI Supplier ID: 11984	Call Warneford Hospital switchboard on 01865 901000 and ask to speak to the Oxford Pharmacy Store on-call team. Once in contact with a member of the OPS on-call team, we will request the following details from you: 1. Quantity of vials required. 2. Order Reference / PO Number (to match the OPS invoice) 3. Delivery details (Hospital name and ward delivery details) 4. Billing details (Hospital name and address) 5. Medical Practitioner details (name and contact number). 6. On-call Pharmacist/Out of Hours contact details (name and contact number for the person receipting the product).

PLEASE NOTE: Four vials (4) are held in Scotland under the Rarely Used Urgent Medicine List Arrangements. To find out more information visit www.toxbase.org

- OPS will arrange a same day, point to point delivery to you via a temperature- controlled courier partner (subject to a delivery cost confirmed prior to dispatch).

- OPS will confirm an estimated time of arrival to your address and request that you confirm receipt of the order. OPS also requests that the person sourcing the product contacts their Pharmacy Procurement team to raise an official Purchase Order once the pharmacy is next open.

- We cannot confirm an exact delivery time prior to an order, this will be dependent upon several factors including, but not limited to time of request, traffic, location, courier availability, weather conditions.

FAQ's

- **'Shall I mark my order as urgent?'** There is no requirement to do this, OPS treats all orders and requests for this product as an immediate urgent requirement.
- **'How quickly can you deliver?'** We will aim to deliver within 10.00 hours of a request. Please note this is an estimate for your delivery, and the exact timing will be confirmed once the order has been received and processed.
- **'Can I send a request outside of OOH?'** Please see noted times above. If you require access outside of these hours, please consider stocking this product locally.

VORAXAZE®▼(glucarpidase) 1,000 units powder for solution for injection.

Please consult Summary of Product Characteristics (SmPC) before prescribing.

Presentation & composition: White to off-white powder for solution for injection.

Indication: To reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination.

Dosage: A single dose of 50 units per kilogram (kg) by bolus intravenous (IV) injection over 5 minutes. Once diagnosis of delayed methotrexate (MTX) elimination or risk of toxicity is established, glucarpidase should be administered without delay, the optimal window is within 48-60 hours from the start of the high dose MTX (HDMTX) infusion. Folinic acid should not be administered within the 2 hours before or after glucarpidase administration. No dose adjustment is recommended for patients with renal impairment. No dose adjustment is required for the paediatric population.

Administration: Glucarpidase is intended for use under medical supervision. In order to take into account all MTX doses and infusion durations that could be administered to a patient, it is recommended to utilise local or national treatment protocols or guidelines if available, to determine when glucarpidase should be administered.

Recommendations for intervention with glucarpidase are considered when plasma MTX levels are greater than 2 standard deviations of the mean expected MTX excretion curve. Administration of Glucarpidase should optimally occur within 60 hours from the start of the HDMTX infusion as life threatening toxicities may not be preventable beyond this time point. Recommendations for intervention with glucarpidase are detailed below:

MTX Dose:	**≤ 1 g/m²**	**1-8 g/m²**	**8-12 g/m²**
Infusion duration:	Over 36-42 hours	Over 24 hours	Over ≤ 6 hours
Hours following start of MTX infusion	Threshold plasma MTX concentration (µM)		
24 hours	-	-*	≥ 50
36 hours	-	≥ 30	≥ 30
42 hours	-	≥ 10	≥ 10
48 hours	≥ 5	≥ 5	≥ 5

* Start supportive care when ≥ 120 µM.

As a further guide for patients receiving short infusion MTX regimens, glucarpidase administration may be considered as detailed below:

MTX Dose:	**3-3.5 g/m²**	**5 g/m²**
Hours following start of MTX infusion	Threshold plasma MTX concentration (µM)	
24 hours	≥ 20	-
36 hours	-	≥ 10
48 hours	≥ 5	≥ 6

Contraindications: Hypersensitivity to active substance or excipients (lactose, trometamol, zinc acetate dihydrate).

Warnings & Precautions:

Traceability:

In order to improve the traceability of biological medicinal products, the tradename and the batch number of the administered product should be clearly recorded.

Paediatric population:

No formal evaluation of the effect of age on the pharmacokinetics of glucarpidase has been performed.

It is important to measure baseline plasma MTX concentrations and renal function and to continue to monitor these throughout treatment with high dose MTX therapy. A high performance chromatography (HPLC) method is recommended for measuring MTX concentrations following glucarpidase administration. Glucarpidase does not reverse pre-existing renal damage or renal failure that occurs as a consequence of MTX administration, but instead removes MTX to reduce the risk of sustaining further renal toxicity. As such, other supportive care, including hydration and alkalinisation of the urine, should be started at the onset of MTX administration and continued in accordance with local treatment guidelines. Allergic type hypersensitivity reactions are possible following administration of glucarpidase, see SmPC.

Interactions: Glucarpidase can decrease folinic acid concentration, which may decrease the effect of folinic acid rescue unless it is dosed as recommended. Glucarpidase may also reduce the concentrations of other folate analogs or folate analog metabolic inhibitors.

Fertility, Pregnancy and lactation: It is unknown whether glucarpidase causes harmful effects during pregnancy and/or on the foetus/newborn child or whether it can affect reproductive capacity. There is no data for the use of Glucarpidase in pregnant women. Glucarpidase should only be given to a pregnant woman if clearly needed. It is unknown whether glucarpidase/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. It is unknown whether glucarpidase affects fertility.

Driving and machines: Glucarpidase has no or negligible influence on the ability to drive and use machines.

Undesirable effects:

Uncommon: Nervous system disorders (burning sesation, headache, paraesthesia), Vascular disorders (flushing), General disorders (feeling hot). **Rare**: Immune system disorders (hypersensitivity), Nervous system disorders (hypoesthesia, somnolence, tremor), Vascular disorders (hypotension), Gastrointestinal disorders (abdominal pain upper, diarrhoea, nausea, vomiting), Skin and subcutaneous tissue disorders (pruritis, rash and General disorders (pyrexia, rebound effect). **Very rare**: Immune system disorders (anaphylactic reaction), Cardiac disorders (tachycardia), Skin and subcutaneous tissue disorders (including drug eruption, skin reaction), Renal disorders (crystalluria) and General disorders (infusion site reaction). See SmPC for further details.

Legal classification: POM

NHS Price: £25385.00

UK (Great Britain) Marketing Authorisation number: PLGB 18442/0002

Marketing Authorisation Holder: Protherics Medicines Development Limited, Blaenwaun Ffostrasol Llandysul Ceredigion, SA44 5JT

Job code: UK-VRX-2500049

Date of Last Revision: September 2025

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to safety@serb.com

ABPI Certification
United Kingdom

Title:	Ordering Glucarpidase (Voraxaze) via Oxford Pharmacy Stores_Scotland inc
Format of final material:	Material
Piece Details:	Audience: Those with budgetary, prescribing or ordering responsibilities. Clinical Pharmacists, Heamo/Oncologists, Procurement Pharmacists, Paed Oncologists, Paed Pharmacists For use by RAMs as printed material and email to requesting HCP (clinical pharmacists etc). OPS will have on file and send to requesting HCPs (see audience) if REPS print they will use A4 paper (double sided with PI on reverse)
Material Intent:	Promotional
Audience:	Distributors HCPs/HCOs Payors
Item code number:	UK-VRX-2400025

ABPI Certification declaration

This is to certify that the medical signatory has examined the final form of this material to which no further changes are to be made, and that in their belief it is ethical, accurate, and in accordance with the requirements of the ABPI Code of Practice both in spirit and letter, as well as with the relevant advertising regulations. In addition, the signatory confirms their belief that the material is not inconsistent with the Marketing Authorization and the Summary of Product Characteristics and is a fair and truthful presentation of the facts about the medicine.

The nominated signatory/appropriately qualified person has examined the final form and confirms their belief that it accurately reflects the content and presentation certified electronically, and complies with the ABPI Code of Practice.

Signatory	Print Name / Date
Medical Signatory	Dolapo Bamiro 04-Feb-2026 12:01:00 GMT+0000